Therapeutic Impact of Gardasil® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients
Viruses · 26.02.2025 · 17 (3) · 321
DOI: 10.3390/v17030321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 26.02.2025. Verfasst von Jennifer Sieg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, Germany. Hauptthemen laut MEDLINE: Papillomavirus Infections, Respiratory Tract Infections, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Papillomavirus Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11. The condition primarily affects the larynx, potentially leading to life-threatening airway obstruction. It is more aggressive in younger patients, necessitating frequent surgical interventions. This study investigates the therapeutic potential of the prophylactic HPV vaccine Gardasil® in RRP patients, focusing on its impact on lesion size and the frequency of surgical interventions. Furthermore, a literature review was conducted to analyze the factors influencing the decision to vaccinate.
Methods
A retrospective analysis was conducted on 63 RRP patients treated from 2008 to 2021. Disease burden was assessed using the Derkay score and the annual frequency of laser-surgical ablations. Comparisons were made between pre- and post-vaccination periods in vaccinated patients (n = 18), and between first and second halves of the disease’s course in unvaccinated patients (n = 14).
Results
A reduction in the frequency of surgical interventions post-vaccination (p < 0.05) could be seen. The cumulated Derkay score per year decreased after second and third vaccination (p < 0.05). The decision to be vaccinated is influenced by multiple factors (e.g., potential side-effects, sociocultural factors, impact of social media, pre-existing conditions and the wider context of the recent pandemic).
Conclusions
Gardasil® appears to reduce the frequency of surgery and lessen disease severity in RRP patients, supporting the potential role of HPV vaccination as a therapeutic option for RRP. Moreover, it is crucial to overcome skepticism towards vaccinations to prevent the development of HPV-associated diseases in the first place.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, Germany.
- Institute of Medical Informatics and Statistics, Christian-Albrechts University Kiel, 24105 Kiel, Germany.
ORCID-Profile: Astrid Dempfle, Susanne Wiegand, Markus Hoffmann
Zitieren
APA
Sieg, J., Fazel, A., Quabius, E. S., Dempfle, A., Wiegand, S., & Hoffmann, M. (2025). Therapeutic Impact of Gardasil® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients. Viruses, 17(3), 321. https://doi.org/10.3390/v17030321
Vancouver
Sieg J, Fazel A, Quabius ES, Dempfle A, Wiegand S, Hoffmann M. Therapeutic Impact of Gardasil® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients. Viruses. 2025;17(3):321. doi:10.3390/v17030321
BibTeX
@article{Sieg2025,
author = {Sieg, Jennifer and Fazel, Asita and Quabius, Elgar Susanne and Dempfle, Astrid and Wiegand, Susanne and Hoffmann, Markus},
title = {Therapeutic Impact of Gardasil® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients},
journal = {Viruses},
year = {2025},
volume = {17},
number = {3},
pages = {321},
doi = {10.3390/v17030321}
}
EUVIMED